Asset 1

Bone Marrow Mononuclear Cells (BMMCs)

Optimize Cohort Selection and Research Outcomes with High Quality, Immunophenotypically Characterized Bone Marrow Mononuclear Cells (BMMCs)

Discovery BMMCs Advantages



BMMCs Matched Sets

Our Discovery Partners® network allows for large-scale, prospective collections of high-quality matched sample sets of human biospecimens. Each matched sample set is provided with the base clinical data from the patient case, along with redacted pathology information.

Discovery’s BMMC Characterization

BMMCs Technical Resources

AML BMMC Technical Data Sheet

Product information for acute myeloid leukemia BMMCs characterized by flow cytometry. Data Sheets

MM BMMC Technical Data Sheet

Product information for multiple myeloma BMMCs characterized by flow cytometry. Data Sheets


Standard processing of diseased bone marrow mononuclear cells (BMMCs). Protocols

Need Molecular Characterization of your BMMCs?

While our biospecimens are highly characterized, we also provide streamlined multi-omic analyses to further characterize biospecimens from our inventory or from your studies via our global CLIA / CAP service laboratories.*

Discovery Genomics


Cell Biology


*Not all service laboratories have CLIA certification or CAP accreditation. Inquire to learn more.

BMMCs Frequently Asked Questions

You can find our BMMCs Protocols by clicking here.

We also have the ability to follow our clients' custom processing protocols and help them develop new processing protocols based on their needs.

Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer.

Cryopreserved vials of BMMCs are pulled from vapor phase LN2 freezers, thawed, and assessed on a Nexcelom Cellometer.

All live-cell products should be stored in the vapor phase of LN2 until thawed for use.

Discovery BMMCs provide post-thaw blast (CD45lo) and plasma cell (CD138+CD38+) counts via flow cytometry. Additionally, blast percentages are taken from the diagnostic Bone Marrow report obtained from the patient's electronic medical record.

Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.


Contact Us Today

Quick Links


Development and Clinical
Trial Solutions